JNJ Ticker Curator

Early win for JNJ's oncology pipeline: Phase 1b combo with docetaxel in mCRPC showed 64.7% patients with >50% PSA reduction and 39.2% with >90% drop...

Key Metrics highlight JNJ's appeal:

• Pharma Giant: $590.8B market cap (100th percentile), $94.2B TTM revenue, 28.5% margin, 9.1% YoY sales growth
  -...

JNJ closed down 0.45% on February 25, 2026, marking a modest pullback described as a mysterious slide without clear catalysts for the healthcare giant.

• FDA approval for monthly subcutaneous RYBREVANT FASPRO + LAZCLUZE in first-line EGFR-mutated advanced NSCLC
• Allows transition to once-monthly...

Johnson & Johnson files FDA sBLA for IMAAVY® in warm autoimmune hemolytic anemia, supported by positive Phase 2/3 data. Pipeline boost targets new indication for investors.

JNJ boosts manufacturing capacity by committing as the first tenant to a suite at Fujifilm Diosynth Biotechnologies' 1M sq ft $2bn plant in North Carolina – key for ramping up future drug output.

Despite Q4 revenue beat to $24.56B (+2.4% QoQ, exceeding estimates by $415.4M), JNJ's non-GAAP EPS was only in-line, prompting an analyst downgrade that its strong run may be ending.

• Intech cut its JNJ position by 4.8%, selling 5,918 shares to hold 116,579 shares worth $21.6M
• Broader activity: Norges Bank took a new $4.9B...

Key metrics showdown:

• JNJ: $590.8B market cap, P/E 22.2, $94.2B revenue (28.5% margin), 9.1% Q sales growth, $11.53 EPS est, 2.1% dividend yield
  -...

Key MedTech expansion for ischemic stroke care:

• CEREGLIDE™ 42/57 aspiration catheters enable distal clot removal with variable stiffness,...

Strategic divestiture sharpens J&J's surgical portfolio focus.

• Deal details: Quantum Surgical acquires NeuWave Medical, J&J's microwave ablation...

Earnings Highlights

• 🔥 EPS Beat: Johnson & Johnson reported quarterly EPS of $2.46, beating Zacks Consensus Estimate of $2.43.
• Net margin of...

• Analyst Consensus: Moderate Buy (27 ratings: 18 Buy, 9 Hold), avg target $232.70 (-5.14% from $245.32)
• Target Range: High $265, low $190
  -...

Key revenue driver: Darzalex hit $14B+ sales in 2025 (+22% YoY), powering 20.9% oncology growth (27% of total rev).

• Pipeline momentum: New drugs...

• Price Snapshot: Closed $245.17 (-0.45%), premarket $244.94 (-0.09%), day range 243.72-247.25 matching 52-week high 247.25; volume 7.7M (85% avg).
  -...

• Over $1B investment in next-gen cell therapy facility in Montgomery County, PA
• Focus: medicines for cancer, chronic conditions, and neurological...

• AlphaCore Capital LLC purchased Johnson & Johnson ($JNJ) shares
• JNJ ranks as Redmond Asset Management LLC's 5th holding
• Follows $2.46 EPS, 28.46% net margin, and 33.04% ROE
• Signals growing institutional confidence in JNJ's post-earnings strength

Key sector shifts affecting JNJ:

• AI diversion eased: Health care stocks sagged early 2025 due to AI hype and regulatory fears (Trump policies, FDA,...

Key earnings highlights:

• Q4 EPS beat: $2.46 vs Zacks $2.43 consensus
• YTD outperformance: +19.64% vs benchmark +0.65%
• 1-Year surge: +54.60% vs...